



Office of Pharmacy Service Prior Authorization Criteria

Daliresp (roflumilast)

Prior authorization requests for Daliresp will be approved if the following criteria are met:

1. Patient is ≥ 40 years of age
2. Diagnosis of severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and an exacerbation requiring hospitalization or systemic glucocorticoids in the preceding six (6) months
FEV1 $\leq 50\%$ predicted and nonreversible obstructive lung disease (FEV1/FVC $\leq 70\%$ and $\leq 12\%$ or 200 ml improvement in FEV1 in response to 4 puffs albuterol)
3. No evidence of moderate to severe liver impairment (Child-Pugh Class B or C)
4. No concurrent rifampin therapy
6. Concurrent therapy with an inhaled corticosteroid and long-acting bronchodilator

PI Forest Pharmaceuticals, Inc.
Subsidiary of Forest Laboratories, Inc.
St. Louis, MO 63045, USA

PL Detail-Document, New Drug: Daliresp (Roflumilast).
Pharmacist's Letter/Prescriber's Letter. July 2011.